Patent 9248136 was granted and assigned to TherapeuticsMD on February, 2016 by the United States Patent and Trademark Office.
Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.